Natural killer cell

Trinity Life Sciences Institutes a Formal Cell and Gene Therapy Center of Excellence

Retrieved on: 
Monday, December 18, 2023
Biotechnology, General Health, Health, HCP, Potential, COE, Natural killer T cell, Patient, Multimedia, Cell, Room, Elephant, Natural killer cell enteropathy, Partnership, Forecasting, Natural killer cell, NK, Center of excellence, Fine chemical, Health care

Trinity Life Sciences , a leader in global life sciences commercialization solutions, introduces a Cell & Gene Therapy (C&GT) Center of Excellence (COE) that supports life sciences companies in successfully commercializing a C&GT asset.

Key Points: 
  • Trinity Life Sciences , a leader in global life sciences commercialization solutions, introduces a Cell & Gene Therapy (C&GT) Center of Excellence (COE) that supports life sciences companies in successfully commercializing a C&GT asset.
  • View the full release here: https://www.businesswire.com/news/home/20231218899992/en/
    Keren Shani, Head of Cell & Gene Therapy at Trinity Life Sciences, speaks with a colleague after an exhilarating strategy session in June 2023.
  • An on-demand webinar, Gene Therapy Uptake: The Elephant in the Room , evaluates the factors that are unique to forecasting gene therapy markets and discusses what companies need to know to maximize their revenue potential.
  • Among other topics, viewers will hear potential pricing strategies to consider—as well as key market drivers and product factors contributing to gene therapy opportunity.

GC Cell Joins U.S Cancer Moonshot Project

Retrieved on: 
Wednesday, October 25, 2023
Knowledge, Cancer Moonshot, Dime, AstraZeneca, H. Lee Moffitt Cancer Center & Research Institute, Multi, Life, Mortality, Yale Physician Associate Program, Monroe Dunaway Anderson, Dana–Farber Cancer Institute, CDMO, Research, CGT, Korean Ministry of Culture, Genomics, Liver cancer, Intel, NK, Partnership, Natural killer cell, Cancer, AI, Johnson & Johnson, Patient, Mayo Clinic, Medical imaging, Pharmaceutical industry, Vaccine, Food, Takeda, Amazon, Oracle

YONGIN, South Korea, Oct. 24, 2023 /PRNewswire/ -- GC Cell, led by CEO James Park, has announced its participation in CancerX, part of the U.S. Cancer Moonshot project. The Cancer Moonshot, an initiative by the Biden administration, aims to reduce cancer patient mortality rates by over 50% over the next 25 years. In February of this year, CancerX, a public-private collaboration led by the Moffitt Cancer Center and the Digital Medicine Society, was established to boost innovation in the fight against cancer as part of the reignited Cancer Moonshot.

Key Points: 
  • YONGIN, South Korea, Oct. 24, 2023 /PRNewswire/ -- GC Cell, led by CEO James Park, has announced its participation in CancerX, part of the U.S. Cancer Moonshot project.
  • The Cancer Moonshot, an initiative by the Biden administration, aims to reduce cancer patient mortality rates by over 50% over the next 25 years.
  • In February of this year, CancerX, a public-private collaboration led by the Moffitt Cancer Center and the Digital Medicine Society, was established to boost innovation in the fight against cancer as part of the reignited Cancer Moonshot.
  • Through Cancer Moonshot participation, GC Cell aims to highlight the importance and potential of cell therapy in cancer treatment.

SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies

Retrieved on: 
Thursday, June 8, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, Cancer, Natural killer cell, Fast track (FDA), Euronext Paris, IPH, Patient, IPHA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, News, Food, Bone marrow, Pharmaceutical industry, Sanofi

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) is pleased to share Sanofi’s news that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for SAR’579 / IPH6101 for the treatment of hematological malignancies.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) is pleased to share Sanofi’s news that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for SAR’579 / IPH6101 for the treatment of hematological malignancies.
  • Fast Track Designation is an FDA process designed to facilitate the development, and expedite the review of, medicines to treat serious conditions and fill unmet medical need.
  • The FDA created this process to help deliver important new drugs to patients earlier, and it covers a broad range of serious illnesses.
  • “It is promising to see SAR’579 / IPH6101 was granted Fast Track Designation in the US for the treatment of hematological malignancies, and congratulate our partner Sanofi on this milestone,” said Mondher Mahjoubi, Chief Executive Officer of Innate Pharma.

GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, May 15, 2023
Therapy, Blood, CSO, G&A, NK, Natural killer cell, CMO, Consultant, MD, Investment, Administration, Transplant, Research and development, Research, European Society of Clinical Microbiology and Infectious Diseases, R, Hand, Regulation of tobacco by the U.S. Food and Drug Administration, IND, Society, Conference, Food, Pharmaceutical industry, Mobile phone, Fine chemical, Cancer

BRISBANE, CALIFORNIA, May 15, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced first quarter 2023 results for the period ended March 31, 2023.

Key Points: 
  • BRISBANE, CALIFORNIA, May 15, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced first quarter 2023 results for the period ended March 31, 2023.
  • The issue was not central to the manufacturing processes for any GT Biopharma-related molecules, and the specific processes remain unaffected.
  • Research and Development (R&D) Expenses: R&D expenses for the first quarter of 2023 were $1.7 million compared to $2.1 million for the same quarter in 2022.
  • Net Loss: The Company reported a net loss of $227,000 for the first quarter of 2023, compared to a net loss of $5.4 million for the same quarter in 2022.

India Cell & Gene Therapy Business Report 2023 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 12, 2023
Health, Pharmaceutical, DNA, Gene, Medication, Natural killer cell, Different, T cell, Type, Purpose, Allogenic succession, Administration, Ophthalmology, Rare, Clifton Springs Hospital & Clinic, Others, RNA therapeutics, Cell, Route of administration, Topical medication, Neurology, Therapy, Human musculoskeletal system, Commercial, Hospital, Research, Biotechnology, Fine chemical, Medical device, Vaccine, Veterinary medicine

1 India Cell and Gene Therapy Market Size and Forecast, 2018-2027

Key Points: 
  • 1 India Cell and Gene Therapy Market Size and Forecast, 2018-2027
    2 India Cell and Gene Therapy Market Share by Different Therapy Segment, 2018-2027
    2.1 India Market Size by Cell and Gene Modified Cell Therapies, 2018-2027
    2.2 India Market Size by Gene Therapy and Genome Therapy, 2018-2027
    2.3 India Cell and Gene Therapy Market Size by DNA & RNA Therapeutics, 2018-2027
    3 India Cell and Gene Therapy Market Share by Purpose of Manufacturing, 2018-2027
    3.1 India Cell and Gene Therapy Market Size by Commercial, 2018-2027
    3.2 India Cell and Gene Therapy Market Size by Clinical, 2018-2027
    4 India Cell and Gene Therapy Market Share by Product, 2018-2027
    5 India Cell and Gene Therapy Market Share by Route of Administration, 2018-2027
    5.1 India Cell and Gene Therapy Market Size by Injectables, 2018-2027
    5.2 India Cell and Gene Therapy Market Size by Topicals, 2018-2027
    5.3 India Cell and Gene Therapy Market Size by Infusions, 2018-2027
    5.4 India Cell and Gene Therapy Market Size by Bioscaffolds, 2018-2027
    6 India Cell and Gene Therapy Market Share by Type of Diseases, 2018-2027
    6.1 India Cell and Gene Therapy Market Size by Rare Diseases, 2018-2027
    6.2 India Cell and Gene Therapy Market Size by Non-Rare Diseases, 2018-2027
    7 India Cell and Gene Therapy Market Share by Type of Cell, 2018-2027
    7.1 India Cell and Gene Therapy Market Size by CAR-T Cell, 2018-2027
    7.2 India Cell and Gene Therapy Market Size by TCR Cell, 2018-2027
    8 India Cell and Gene Therapy Market Share by Therapy, 2018-2027
    8.1 India Cell and Gene Therapy Market Size by T-Cell Therapies, 2018-2027
    8.2 India Cell and Gene Therapy Market Size by NK Cell, 2018-2027
    8.3 India Cell and Gene Therapy Market Size by Dendritic Cell Therapies, 2018-2027
    8.4 India Cell and Gene Therapy Market Size by Stem Cell Therapies, 2018-2027
    9 India Cell and Gene Therapy Market Share by Source of Cell, 2018-2027
    9.1 India Cell and Gene Therapy Market Size by Autologous, 2018-2027
    9.2 India Cell and Gene Therapy Market Size by Allogenic, 2018-2027
    10 India Cell and Gene Therapy Market Share by Delivery Mode, 2018-2027
    10.1 India Cell and Gene Therapy Market Size by In-vivo, 2018-2027
    10.2 India Cell and Gene Therapy Market Size by Ex-vivo, 2018-2027
    11 India Cell and Gene Therapy Market Share by Source of Manufacturing, 2018-2027
    11.1 India Cell and Gene Therapy Market Size by In-House, 2018-2027
    11.2 India Cell and Gene Therapy Market Size by Contract Manufacturing, 2018-2027
    12 India Cell and Gene Therapy Market Share by Therapeutic Class, 2018-2027
    12.1 India Cell and Gene Therapy Market Size by Oncology, 2018-2027
    12.2 India Cell and Gene Therapy Market Size by Neurology, 2018-2027
    12.3 India Cell and Gene Therapy Market Size by Ophthalmology, 2018-2027
    12.4 India Cell and Gene Therapy Market Size by Musculoskeletal, 2018-2027
    12.5 India Cell and Gene Therapy Market Size by Others, 2018-2027
    13 India Cell and Gene Therapy Market Share by Technology, 2018-2027
    13.1 India Cell and Gene Therapy Market Size by Viral Vector Technology, 2018-2027
    13.2 India Cell and Gene Therapy Market Size by Cell Immortalization Technology, 2018-2027
    13.3 India Cell and Gene Therapy Market Size by Genome Editing Technology, 2018-2027
    13.4 India Cell and Gene Therapy Market Size by Others Technologies, 2018-2027
    14 India Cell and Gene Therapy Market Share by End User, 2018-2027
    14.1 India Cell and Gene Therapy Market Size by Pharmaceutical & Biotechnology Companies, 2018-2027
    14.2 India Cell and Gene Therapy Market Size by Academic & Research Institutes, 2018-2027
    14.3 India Cell and Gene Therapy Market Size by Hospital & Clinics, 2018-2027

Innate Pharma Announces Exclusive License of Antibodies to Takeda for Celiac Disease Research Program

Retrieved on: 
Monday, April 3, 2023
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, Coeliac disease, ADC, Euronext Paris, Antibody-drug conjugate, IPH, Natural killer cell, IPHA, Takeda, Antibody, Vaccine, Innate Immunotherapeutics

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) today announced that it has entered into an exclusive license agreement with Takeda under which Innate grants Takeda exclusive worldwide rights to research and develop antibody drug conjugates (ADC) using a panel of selected Innate antibodies against an undisclosed target, with a primary focus in Celiac disease.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) today announced that it has entered into an exclusive license agreement with Takeda under which Innate grants Takeda exclusive worldwide rights to research and develop antibody drug conjugates (ADC) using a panel of selected Innate antibodies against an undisclosed target, with a primary focus in Celiac disease.
  • Takeda will be responsible for the future development, manufacture and commercialization of any potential products developed using the licensed antibodies.
  • “We are thrilled to be working with Takeda, a company which has been very successful in developing new drugs across multiple therapeutic areas.
  • This agreement expands the application of Innate’s science beyond our oncology focus and demonstrates how our antibody engineering expertise can play a major role in developing Antibody Drug Conjugate formats.

Global Natural Killer (NK) Cell Therapeutics Market Trends, Competitive Landscape & Clinical Trials Insights Report 2023 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 30, 2023
Health, Other Health, Tissue, Natural killer cell, CRS, Indication, MHC, Cancer, NK, Cell, German Cancer Research Center, German Cancer Aid, Granzyme, Hematological Cancer Research Investment and Education Act, TCR, Cytokine release syndrome, Patient, Immune system, Sanofi, Canadian Aviation Regulations, Growth, Neoplasm, Fred Hutchinson Cancer Research Center, Recurrence, Partnership, Vaccine, Pharmaceutical industry

The "Global Natural Killer (NK) Cell Therapeutics Market Trends, Companies & Clinical Trials Insight 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Natural Killer (NK) Cell Therapeutics Market Trends, Companies & Clinical Trials Insight 2023" report has been added to ResearchAndMarkets.com's offering.
  • To carry out its cytotoxic activity, NK cells contain granzymes and perforins which cause the target cell to lyse.
  • For a NK cell therapy, the process of generation of NK cells is the same as that for T cell therapy.
  • Partnerships & Funding for Natural Killer Cell Therapies: > 10 Recent Deals
    Global Natural Killer Cell Therapies Clinical Trials Insight: > 200 Therapies
    Global Natural Killer Cell Therapies Clinical Trials by Company, Indication & Phase
    Proprietary Technologies by Company Insight: > 10 Technologies

Celularity Completes Strategic Review of 2023 Initiatives, Including Anticipated Biomaterials Production Ramp-Up and Pipeline Prioritization of Next-Generation Product Candidates

Retrieved on: 
Thursday, January 26, 2023
AML, Placenta, Employment, Natural killer cell, ECM, ASX, Osteoarthritis, Safety, Stomach, Trauma, CELU, OA, IND, KOA, Wound healing, TCR, CH, Synovial fluid, Chondrogenesis, Therapy, Cytokine, Umbilical cord, Muscular dystrophy, GBM, Cartilage, Neoplasm, CAR, NK, Patient, Knee, FDA, CD19, Glioblastoma, FSHD, Instituto de Biologia Molecular e Celular, IMU, Workforce, J. E. M. Ag Supply, Inc. v. Pioneer Hi-Bred International, Inc., Hematological Cancer Research Investment and Education Act, World Health Organization, National academy, Pain, Pharmaceutical industry, Fine chemical, Silk, Phosphorus, Vaccine

FLORHAM PARK, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity,” the “Company”), a U.S.-based biotechnology company developing placental-derived allogenic cell therapies and biomaterial-based regenerative therapeutics products, announced today the results of a strategic review of its 2023 key initiatives. This strategic review included the recently announced territory distribution agreement covering more than 100 countries for Celularity’s Halal-Certified products and the exclusive distribution agreement with the Tamer Group in Saudi Arabia. Celularity’s review also included pipeline prioritization and targeted expense reductions to align operating priorities in advance of an anticipated biomaterials production ramp-up this year.

Key Points: 
  • Celularity’s review also included pipeline prioritization and targeted expense reductions to align operating priorities in advance of an anticipated biomaterials production ramp-up this year.
  • Celularity’s advanced biomaterial products include:
    Biovance®, a decellularized, dehydrated human amniotic membrane derived from the placenta of a healthy, full-term pregnancy.
  • Celularity continues to believe that genetically modified NK cells will be an important option to improve the current standard of care.
  • However, given the Company’s strategic review, it will deprioritize this study while it continues to optimize its modified and unmodified NK cell platform.

Innate Pharma Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology

Retrieved on: 
Monday, January 16, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Other Health, CD16, DVM, Toxicity, Nature Biotechnology, Euronext Paris, AML, Doctor of Philosophy, Primate, Acute lymphoblastic leukemia, Acute myeloid leukemia, ADCC, IPHA, Safety, CD64, Natural killer cell, NK, Patient, Cancer, CD123, Antibody opsonization, IPH, B-ALL, Fine chemical, Sanofi, NCR1, Intrinsic and extrinsic properties

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today the publication in Nature Biotechnology of preclinical data showing the control of acute myeloid leukemia (AML) cells by a trifunctional NKp46-CD16a-NK cell engager (NKCE) targeting CD123.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today the publication in Nature Biotechnology of preclinical data showing the control of acute myeloid leukemia (AML) cells by a trifunctional NKp46-CD16a-NK cell engager (NKCE) targeting CD123.
  • The studies were conducted by Innate and Sanofi and published in Nature Biotechnology on January 12, 2023.
  • A Phase 1/2 clinical trial by Sanofi is ongoing, evaluating IPH6101/SAR’579 (SAR443579), the first NKp46/CD16-based CD123-targeted ANKETTM NK cell engager, in patients with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL) or high-risk myelodysplastic syndrome (HR-MDS).
  • We're pleased with our productive collaboration with Innate Pharma, and data like this reinforce our confidence in proceeding to clinical evaluation of this novel NK cell engager."

Press Release: Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology

Retrieved on: 
Monday, December 19, 2022
Natural killer cell, Partnership, HSR, Euronext Paris, Patient, NK, IPHA, IPH, Fine chemical, Intrinsic and extrinsic properties, Sanofi

Upon candidate selection, Sanofi will be responsible for all development, manufacturing and commercialization.

Key Points: 
  • Upon candidate selection, Sanofi will be responsible for all development, manufacturing and commercialization.
  • Innate and Sanofi signed a first NK cell engagers collaboration in 2016 for the generation and evaluation of up to two bispecific NK cell engagers, which are currently being evaluated by Sanofi’s R&D team, with one of these molecules already in clinical studies.
  • “At Sanofi, we are exploring the potential of NK cells for cancer immunotherapy, a key pillar for our oncology strategy.
  • Sanofi’s investment in Innate further validate the value of our ANKETTM platform and its potential to address multiple tumor types.